GlassScriptPhysician profile
Daniel C Henshaw
NPI 1295992949
$787.73
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $274 · 2022: $492 · 2023: $21.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $21.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $21.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $212.66 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $74.44 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $59.12 | 2021-2022 | |
| Glaxosmithkline, LLC. | $55.30 | 2021-2022 | |
| Novo Nordisk INC | $54.59 | 2022 | |
| Amgen INC. | $52.34 | 2022 | |
| Antares Pharma, INC. | $49.85 | 2022 | |
| Lilly USA, LLC | $46.22 | 2021-2022 | |
| Abbott Laboratories | $45.19 | 2021-2023 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $37.67 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.31 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.61 | 2021 | |
| Xeris Pharmaceuticals, INC. | $15.97 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.22 | 2022 | |
| Currax Pharmaceuticals LLC | $13.62 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Henshaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.